Sign up for the QMED & MD+DI Daily newsletter.
April 22, 2022
1 Min Read
Image courtesy of Serhii Vasylevskyi / Alamy Stock Photo
Microvention, a wholly owned subsidiary of Terumo Corp., recently completed its first enrollment in the STRAIT study of its BOBBY balloon-guide catheter. “The STRAIT trial is intended to provide clinical evidence that Microvention’s new balloon guide catheter can effectively contribute to improved clinical outcomes,” said company president and CEO, Carsten Schroeder.
BOBBY is designed to streamline balloon preparation while improving navigability and ensuring compatibility with the company’s SOFIA Plus 6Fr aspiration catheter. It is currently approved in Europe and North America. The device is intended for use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel in the peripheral and neurovascular systems. The balloon provides temporary vascular occlusion during these and other angiographic procedures. It is also indicated for use as a conduit for retrieval devices.
The first patient for the STRAIT study was enrolled at the site of principal investigator PD Dr. med Tobias Boeckh-Behrens, Department of Diagnostic and Interventional Neuro Radiology.
“A severe stroke case with a left carotid occlusion was successfully treated with the use of BOBBY, resulting in a first pass TICI 3, 20 minutes after groin procedure,” commented Dr. med Christian Maegerlein, who treated the patient with BOBBY. “We were pleased with the excellent performance of the BOBBY BGC with the SOFIA Plus 6Fr aspiration catheter, Headway microcatheter, Traxcess EX guidewire, and the 6 x 40 stent retriever revascularization device.”
You May Also Like
Masimo Takes Apple's Hail Mary Pass in StrideFeb 29, 2024|3 Min Read
Top 40 Medical Device CompaniesFeb 29, 2024|2 Min Read
2024 Planning Guide for Medical Manufacturing AutomationFeb 29, 2024|1 Min Read
Adverse Events Reported for Hologic BioZorb Marker, BioZorb LP MarkerFeb 28, 2024|2 Min Read